Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 46 entries
Sorted by: Best Match Show Resources per page
Neuroprotective Therapies for Spontaneous Intracerebral Hemorrhage.

Neurocritical care

Kearns KN, Ironside N, Park MS, Worrall BB, Southerland AM, Chen CJ, Ding D.
PMID: 34341912
Neurocrit Care. 2021 Dec;35(3):862-886. doi: 10.1007/s12028-021-01311-3. Epub 2021 Aug 02.

Patients who survive the initial ictus of spontaneous intracerebral hemorrhage (ICH) remain vulnerable to subsequent injury of the perilesional parenchyma by molecular and cellular responses to the hematoma. Secondary brain injury after ICH, which contributes to long-term functional impairment...

Cite
Kearns KN, Ironside N, Park MS, et al. Neuroprotective Therapies for Spontaneous Intracerebral Hemorrhage. Neurocrit Care. 2021;35(3):862-886doi: 10.1007/s12028-021-01311-3.
Kearns, K. N., Ironside, N., Park, M. S., Worrall, B. B., Southerland, A. M., Chen, C. J., & Ding, D. (2021). Neuroprotective Therapies for Spontaneous Intracerebral Hemorrhage. Neurocritical care, 35(3), 862-886. https://doi.org/10.1007/s12028-021-01311-3
Kearns, Kathryn N, et al. "Neuroprotective Therapies for Spontaneous Intracerebral Hemorrhage." Neurocritical care vol. 35,3 (2021): 862-886. doi: https://doi.org/10.1007/s12028-021-01311-3
Kearns KN, Ironside N, Park MS, Worrall BB, Southerland AM, Chen CJ, Ding D. Neuroprotective Therapies for Spontaneous Intracerebral Hemorrhage. Neurocrit Care. 2021 Dec;35(3):862-886. doi: 10.1007/s12028-021-01311-3. Epub 2021 Aug 02. PMID: 34341912.
Copy Download .nbib Format: NLM
The impact of ionization States of matrix metalloproteinase inhibitors on docking-based inhibitor design.

ACS medicinal chemistry letters

Zhong H, Wees MA, Faure TD, Carrillo C, Arbiser J, Bowen JP.
PMID: 24900330
ACS Med Chem Lett. 2011 Mar 29;2(6):455-60. doi: 10.1021/ml200031m. eCollection 2011 Jun 09.

The influence of ionization states of hydroxamates and retrohydroxamates and the presence of zinc ions in the active site were investigated using the wild-type and E402Q mutant of MMP-9. The deprotonated hydroxamates showed a significantly enhanced enrichment factor in...

Cite
Zhong H, Wees MA, Faure TD, et al. The impact of ionization States of matrix metalloproteinase inhibitors on docking-based inhibitor design. ACS Med Chem Lett. 2011;2(6):455-60doi: 10.1021/ml200031m.
Zhong, H., Wees, M. A., Faure, T. D., Carrillo, C., Arbiser, J., & Bowen, J. P. (2011). The impact of ionization States of matrix metalloproteinase inhibitors on docking-based inhibitor design. ACS medicinal chemistry letters, 2(6), 455-60. https://doi.org/10.1021/ml200031m
Zhong, Haizhen, et al. "The impact of ionization States of matrix metalloproteinase inhibitors on docking-based inhibitor design." ACS medicinal chemistry letters vol. 2,6 (2011): 455-60. doi: https://doi.org/10.1021/ml200031m
Zhong H, Wees MA, Faure TD, Carrillo C, Arbiser J, Bowen JP. The impact of ionization States of matrix metalloproteinase inhibitors on docking-based inhibitor design. ACS Med Chem Lett. 2011 Mar 29;2(6):455-60. doi: 10.1021/ml200031m. eCollection 2011 Jun 09. PMID: 24900330; PMCID: PMC4018105.
Copy Download .nbib Format: NLM
(2-Aminobenzothiazole)-Methyl-1,1-Bisphosphonic Acids: Targeting Matrix Metalloproteinase 13 Inhibition to the Bone.

Pharmaceuticals (Basel, Switzerland)

Laghezza A, Piemontese L, Brunetti L, Caradonna A, Agamennone M, Loiodice F, Tortorella P.
PMID: 33498946
Pharmaceuticals (Basel). 2021 Jan 24;14(2). doi: 10.3390/ph14020085.

Matrix Metalloproteinases (MMPs) are a family of secreted and membrane-bound enzymes, of which 24 isoforms are known in humans. These enzymes degrade the proteins of the extracellular matrix and play a role of utmost importance in the physiological remodeling...

Cite
Laghezza A, Piemontese L, Brunetti L, et al. (2-Aminobenzothiazole)-Methyl-1,1-Bisphosphonic Acids: Targeting Matrix Metalloproteinase 13 Inhibition to the Bone. Pharmaceuticals (Basel). 2021;14(2)doi: 10.3390/ph14020085.
Laghezza, A., Piemontese, L., Brunetti, L., Caradonna, A., Agamennone, M., Loiodice, F., & Tortorella, P. (2021). (2-Aminobenzothiazole)-Methyl-1,1-Bisphosphonic Acids: Targeting Matrix Metalloproteinase 13 Inhibition to the Bone. Pharmaceuticals (Basel, Switzerland), 14(2), . https://doi.org/10.3390/ph14020085
Laghezza, Antonio, et al. "(2-Aminobenzothiazole)-Methyl-1,1-Bisphosphonic Acids: Targeting Matrix Metalloproteinase 13 Inhibition to the Bone." Pharmaceuticals (Basel, Switzerland) vol. 14,2 (2021). doi: https://doi.org/10.3390/ph14020085
Laghezza A, Piemontese L, Brunetti L, Caradonna A, Agamennone M, Loiodice F, Tortorella P. (2-Aminobenzothiazole)-Methyl-1,1-Bisphosphonic Acids: Targeting Matrix Metalloproteinase 13 Inhibition to the Bone. Pharmaceuticals (Basel). 2021 Jan 24;14(2). doi: 10.3390/ph14020085. PMID: 33498946; PMCID: PMC7912614.
Copy Download .nbib Format: NLM
Structure-based molecular insights into matrix metalloproteinase inhibitors in cancer treatments.

Future medicinal chemistry

Lin H, Xu P, Huang M.
PMID: 34779649
Future Med Chem. 2021 Nov 15; doi: 10.4155/fmc-2021-0246. Epub 2021 Nov 15.

Protease inhibitors are of considerable interest as anticancer agents. Matrix metalloproteinases (MMPs) were the earliest type of proteases considered as anticancer targets. The developments of MMP inhibitors (MMPIs) by pharmaceutical companies can be dated from the early 1980s. Thus...

Cite
Lin H, Xu P, Huang M. Structure-based molecular insights into matrix metalloproteinase inhibitors in cancer treatments. Future Med Chem. 2021;doi: 10.4155/fmc-2021-0246.
Lin, H., Xu, P., & Huang, M. (2021). Structure-based molecular insights into matrix metalloproteinase inhibitors in cancer treatments. Future medicinal chemistry, . https://doi.org/10.4155/fmc-2021-0246
Lin, Haili, et al. "Structure-based molecular insights into matrix metalloproteinase inhibitors in cancer treatments." Future medicinal chemistry vol. (2021). doi: https://doi.org/10.4155/fmc-2021-0246
Lin H, Xu P, Huang M. Structure-based molecular insights into matrix metalloproteinase inhibitors in cancer treatments. Future Med Chem. 2021 Nov 15; doi: 10.4155/fmc-2021-0246. Epub 2021 Nov 15. PMID: 34779649.
Copy Download .nbib Format: NLM
The Goal of Cancer Treatment.

The oncologist

Balis FM.
PMID: 10388118
Oncologist. 1998;3(4):V.

As clinical oncologists, our ultimate goal in treating patients with cancer is to be able to cure their disease with a combination of treatment modalities directed at the primary tumor (surgery or radiation), and potential metastases (chemotherapy). The validity...

Cite
Balis FM. The Goal of Cancer Treatment. Oncologist. 1998;3(4):V
Balis, F. M. (1998). The Goal of Cancer Treatment. The oncologist, 3(4), V.
Balis. "The Goal of Cancer Treatment." The oncologist vol. 3,4 (1998): V.
Balis FM. The Goal of Cancer Treatment. Oncologist. 1998;3(4):V. PMID: 10388118.
Copy Download .nbib Format: NLM
Design and therapeutic application of matrix metalloproteinase inhibitors. (Chem. Rev. 1999, 99, 2735-2776. Published on the web september 8, 1999).

Chemical reviews

Whittaker M, Floyd CD, Brown P, Gearing AJ.
PMID: 11749369
Chem Rev. 2001 Jul 11;101(7):2205-6. doi: 10.1021/cr0100345.

No abstract available.

Cite
Whittaker M, Floyd CD, Brown P, et al. Design and therapeutic application of matrix metalloproteinase inhibitors. (Chem. Rev. 1999, 99, 2735-2776. Published on the web september 8, 1999). Chem Rev. 2001;101(7):2205-6doi: 10.1021/cr0100345.
Whittaker, M., Floyd, C. D., Brown, P., & Gearing, A. J. (2001). Design and therapeutic application of matrix metalloproteinase inhibitors. (Chem. Rev. 1999, 99, 2735-2776. Published on the web september 8, 1999). Chemical reviews, 101(7), 2205-6. https://doi.org/10.1021/cr0100345
Whittaker, M, et al. "Design and therapeutic application of matrix metalloproteinase inhibitors. (Chem. Rev. 1999, 99, 2735-2776. Published on the web september 8, 1999)." Chemical reviews vol. 101,7 (2001): 2205-6. doi: https://doi.org/10.1021/cr0100345
Whittaker M, Floyd CD, Brown P, Gearing AJ. Design and therapeutic application of matrix metalloproteinase inhibitors. (Chem. Rev. 1999, 99, 2735-2776. Published on the web september 8, 1999). Chem Rev. 2001 Jul 11;101(7):2205-6. doi: 10.1021/cr0100345. PMID: 11749369.
Copy Download .nbib Format: NLM
Design and therapeutic application of matrix metalloproteinase inhibitors.

Chemical reviews

Whittaker M, Floyd CD, Brown P, Gearing AJ.
PMID: 11749499
Chem Rev. 1999 Sep 08;99(9):2735-76. doi: 10.1021/cr9804543.

No abstract available.

Cite
Whittaker M, Floyd CD, Brown P, et al. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev. 1999;99(9):2735-76doi: 10.1021/cr9804543.
Whittaker, M., Floyd, C. D., Brown, P., & Gearing, A. J. (1999). Design and therapeutic application of matrix metalloproteinase inhibitors. Chemical reviews, 99(9), 2735-76. https://doi.org/10.1021/cr9804543
Whittaker, M, et al. "Design and therapeutic application of matrix metalloproteinase inhibitors." Chemical reviews vol. 99,9 (1999): 2735-76. doi: https://doi.org/10.1021/cr9804543
Whittaker M, Floyd CD, Brown P, Gearing AJ. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev. 1999 Sep 08;99(9):2735-76. doi: 10.1021/cr9804543. PMID: 11749499.
Copy Download .nbib Format: NLM
New anti-angiogenesis agents: review of the clinical experience with carboxyamido-triazole (CAI), thalidomide, TNP-470 and interleukin-12.

Angiogenesis

Masiero L, Figg WD, Kohn EC.
PMID: 14517390
Angiogenesis. 1997;1(1):23-35. doi: 10.1023/A:1018301031580.

Angiogenesis was postulated to be a critical prognostic factor and therapeutic focus for malignancy more than two decades ago. Recent studies indicate quantitative assessments of microvessel count to be an independent prognostic variable for disease-free and overall survival in...

Cite
Masiero L, Figg WD, Kohn EC. New anti-angiogenesis agents: review of the clinical experience with carboxyamido-triazole (CAI), thalidomide, TNP-470 and interleukin-12. Angiogenesis. 1997;1(1):23-35doi: 10.1023/A:1018301031580.
Masiero, L., Figg, W. D., & Kohn, E. C. (1997). New anti-angiogenesis agents: review of the clinical experience with carboxyamido-triazole (CAI), thalidomide, TNP-470 and interleukin-12. Angiogenesis, 1(1), 23-35. https://doi.org/10.1023/A:1018301031580
Masiero, L, et al. "New anti-angiogenesis agents: review of the clinical experience with carboxyamido-triazole (CAI), thalidomide, TNP-470 and interleukin-12." Angiogenesis vol. 1,1 (1997): 23-35. doi: https://doi.org/10.1023/A:1018301031580
Masiero L, Figg WD, Kohn EC. New anti-angiogenesis agents: review of the clinical experience with carboxyamido-triazole (CAI), thalidomide, TNP-470 and interleukin-12. Angiogenesis. 1997;1(1):23-35. doi: 10.1023/A:1018301031580. PMID: 14517390.
Copy Download .nbib Format: NLM
Recurrent Corneal Erosion Syndrome.

Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)

Xu K, Kam KW, Young AL, Jhanji V.
PMID: 26107728
Asia Pac J Ophthalmol (Phila). 2012 Nov-Dec;1(6):349-54. doi: 10.1097/APO.0b013e31827347ae.

Recurrent corneal erosion syndrome is characterized by repeated episodes of sudden onset of pain usually upon awakening or at night because of detachment of the weakly adhered corneal epithelium. Most of the cases can be attributed to trauma or...

Cite
Xu K, Kam KW, Young AL, et al. Recurrent Corneal Erosion Syndrome. Asia Pac J Ophthalmol (Phila). 2012;1(6):349-54doi: 10.1097/APO.0b013e31827347ae.
Xu, K., Kam, K. W., Young, A. L., & Jhanji, V. (2012). Recurrent Corneal Erosion Syndrome. Asia-Pacific journal of ophthalmology (Philadelphia, Pa.), 1(6), 349-54. https://doi.org/10.1097/APO.0b013e31827347ae
Xu, Kunyong, et al. "Recurrent Corneal Erosion Syndrome." Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) vol. 1,6 (2012): 349-54. doi: https://doi.org/10.1097/APO.0b013e31827347ae
Xu K, Kam KW, Young AL, Jhanji V. Recurrent Corneal Erosion Syndrome. Asia Pac J Ophthalmol (Phila). 2012 Nov-Dec;1(6):349-54. doi: 10.1097/APO.0b013e31827347ae. PMID: 26107728.
Copy Download .nbib Format: NLM
Matrix metalloproteinase inhibitors attenuate neuroinflammation following focal cerebral ischemia in mice.

The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology

Park CH, Shin TK, Lee HY, Kim SJ, Lee WS.
PMID: 21660152
Korean J Physiol Pharmacol. 2011 Apr;15(2):115-22. doi: 10.4196/kjpp.2011.15.2.115. Epub 2011 Apr 30.

The aim of this study was to investigate whether matrix metalloproteinase (MMP) inhibitors attenuate neuroinflammation in an ischemic brain following photothrombotic cortical ischemia in mice. Male C57BL/6 mice were anesthetized, and Rose Bengal was systemically administered. Permanent focal ischemia...

Cite
Park CH, Shin TK, Lee HY, et al. Matrix metalloproteinase inhibitors attenuate neuroinflammation following focal cerebral ischemia in mice. Korean J Physiol Pharmacol. 2011;15(2):115-22doi: 10.4196/kjpp.2011.15.2.115.
Park, C. H., Shin, T. K., Lee, H. Y., Kim, S. J., & Lee, W. S. (2011). Matrix metalloproteinase inhibitors attenuate neuroinflammation following focal cerebral ischemia in mice. The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology, 15(2), 115-22. https://doi.org/10.4196/kjpp.2011.15.2.115
Park, Cheol Hong, et al. "Matrix metalloproteinase inhibitors attenuate neuroinflammation following focal cerebral ischemia in mice." The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology vol. 15,2 (2011): 115-22. doi: https://doi.org/10.4196/kjpp.2011.15.2.115
Park CH, Shin TK, Lee HY, Kim SJ, Lee WS. Matrix metalloproteinase inhibitors attenuate neuroinflammation following focal cerebral ischemia in mice. Korean J Physiol Pharmacol. 2011 Apr;15(2):115-22. doi: 10.4196/kjpp.2011.15.2.115. Epub 2011 Apr 30. PMID: 21660152; PMCID: PMC3104200.
Copy Download .nbib Format: NLM
Matrix metalloproteinase inhibitors.

IDrugs : the investigational drugs journal

Zhang Y.
PMID: 18465633
IDrugs. 1998 Nov;1(7):750-1.

The Division of Medicinal Chemistry offered a number of sub-sessions including this one on matrix metalloproteinase (MMP) inhibitors. The overexpression of matrix metalloproteinases has been associated with cancer malignancy, arthritis and several immune system-related infectious diseases such as sepsis....

Cite
Zhang Y. Matrix metalloproteinase inhibitors. IDrugs. 1998;1(7):750-1
Zhang, Y. (1998). Matrix metalloproteinase inhibitors. IDrugs : the investigational drugs journal, 1(7), 750-1.
Zhang, Y. "Matrix metalloproteinase inhibitors." IDrugs : the investigational drugs journal vol. 1,7 (1998): 750-1.
Zhang Y. Matrix metalloproteinase inhibitors. IDrugs. 1998 Nov;1(7):750-1. PMID: 18465633.
Copy Download .nbib Format: NLM
Matrix metalloproteinase inhibitors in cancer: an update.

IDrugs : the investigational drugs journal

Marshall JL, Baidas S, Bhargava P, Rizvi N.
PMID: 16100684
IDrugs. 2000 May;3(5):518-24.

No abstract available.

Cite
Marshall JL, Baidas S, Bhargava P, et al. Matrix metalloproteinase inhibitors in cancer: an update. IDrugs. 2000;3(5):518-24
Marshall, J. L., Baidas, S., Bhargava, P., & Rizvi, N. (2000). Matrix metalloproteinase inhibitors in cancer: an update. IDrugs : the investigational drugs journal, 3(5), 518-24.
Marshall, J L, et al. "Matrix metalloproteinase inhibitors in cancer: an update." IDrugs : the investigational drugs journal vol. 3,5 (2000): 518-24.
Marshall JL, Baidas S, Bhargava P, Rizvi N. Matrix metalloproteinase inhibitors in cancer: an update. IDrugs. 2000 May;3(5):518-24. PMID: 16100684.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 46 entries